The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I]

##STR00001##

wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like. In addition, the compound of the present invention can be a more effective antitumor agent when used in combination with other antitumor agents such as an alkylating agent or metabolism antagonist.

The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I]

##STR00001##

wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like. In addition, the compound of the present invention can be a more effective antitumor agent when used in combination with other antitumor agents such as an alkylating agent or metabolism antagonist.

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

A compound, or a protonate or salt thereof, having a formula I of: wherein Y represents an optionally substituted aromatic group; n is 1 or 2; a is 0 to 4; R.sup.1 and R.sup.2 are each independently H; optionally substituted alkyl; optionally substituted aralkyl; acyl; phosphonyl; SO.sub.2R.sup.12; C(O)R.sup.13; C(O)OR.sup.14; C(O)NR.sup.15R.sup.16; C(O)CH.sub.2R.sup.17; or C(S)NR.sup.18R.sup.19; S(O)R20; or SO.sub.2NR.sup.21R.sup.22, wherein R.sup.12-R.sup.22 are each independently H, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted aryl, or C(O)R.sup.23, wherein R.sup.23 is H, optionally substituted alkyl, optionally substituted aralkyl, or optionally substituted aryl; and each R.sup.3 is independently optionally substituted alkyl, halogen, optionally substituted alkoxy, optionally substituted carboxyl, amide; amino; or nitro.

A compound, or a protonate or salt thereof, having a formula I of: wherein Y represents an optionally substituted aromatic group; n is 1 or 2; a is 0 to 4; R.sup.1 and R.sup.2 are each independently H; optionally substituted alkyl; optionally substituted aralkyl; acyl; phosphonyl; SO.sub.2R.sup.12; C(O)R.sup.13; C(O)OR.sup.14; C(O)NR.sup.15R.sup.16; C(O)CH.sub.2R.sup.17; or C(S)NR.sup.18R.sup.19; S(O)R20; or SO.sub.2NR.sup.21R.sup.22, wherein R.sup.12-R.sup.22 are each independently H, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted aryl, or C(O)R.sup.23, wherein R.sup.23 is H, optionally substituted alkyl, optionally substituted aralkyl, or optionally substituted aryl; and each R.sup.3 is independently optionally substituted alkyl, halogen, optionally substituted alkoxy, optionally substituted carboxyl, amide; amino; or nitro.

The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.

The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.

Novel diphenylurea and benzylbenzenesulfonamide compounds are disclosed along with methods of inhibiting the activity of TRPV1 and methods of treating pain associated with transient receptor potential vanilloid type 1 (TRPV1) using such compounds.

Novel diphenylurea and benzylbenzenesulfonamide compounds are disclosed along with methods of inhibiting the activity of TRPV1 and methods of treating pain associated with transient receptor potential vanilloid type 1 (TRPV1) using such compounds.